Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.

Frontiers in immunology - 1 Jan 2021

Deshpande Ashlesha, Harris Bethany D, Martinez-Sobrido Luis, Kobie James J, Walter Mark R

Abstract excerpt

Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease 2019 (COVID19) that is responsible for short and long-term disease, as well as death, in susceptible hosts. The receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) protein binds to cell surface angiotensin converting enzyme type-II (ACE2) to initiate viral attachment and ultimately viral pathogenesis. The SARS-CoV-2 S RBD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to Binding Sites, Antibody

Share to Epitopes, B-Lymphocyte

Share to Protein Interaction Domains and Motifs

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34149735
DOI: 10.3389/fimmu.2021.691715
PMCID: PMC8212047

Genes

ACE2
C2
C1D
C3

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.PMID 34149735Read ↗

Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concernSemantic proximity Read ↗

SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.Semantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

Neutralizing antibodies for the prevention and treatment of COVID-19Semantic proximity Read ↗

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBDSemantic proximity Read ↗

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.Semantic proximity Read ↗

Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.Semantic proximity Read ↗

Comprehensive Mapping of Binding Hot Spots of SARS-CoV-2 RBD-specific Neutralizing Antibodies for Tracking Immune Escape VariantsSemantic proximity Read ↗

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding DomainSemantic proximity Read ↗

Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.Semantic proximity Read ↗

A novel consensus‐based computational pipeline for screening of antibody therapeutics for efficacy against SARS‐CoV‐2 variants of concern including Omicron variantSemantic proximity Read ↗

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.